Growth inhibition by phospholipase C inhibitor peptides of colorectal carcinoma cells derived from familial adenomatous polyposis.
We reported previously the enhanced phosphoinositide metabolism and constitutive activation of phosphoinositide-specific phospholipase C (PLC) in two colorectal carcinoma cell lines, KMS-4 and KMS-8, derived from familial adenomatous polyposis patients. To study the physiological role of enhanced PLC activity in these cells, we analyzed the effect of PLC inhibitor (PCI) peptides on their growth and cell cycle. N-Myristoylated PCI peptide, myr-PCI(Y), originally developed based on the PCI sequence of PLC-gamma 2, inhibited activity of purified PLC isoforms in vitro. When myr-PCI(Y) was added to KMS-4 and KMS-8 cultures, it suppressed the production of inositol trisphosphate, DNA synthesis, and cell growth, all of which were induced by serum in both KMS-4 and KMS-8 cells. The number of colonies grown in soft agar was also reduced significantly by treating KMS-8 cells with myr-PCI(Y) peptide. Flow cytometry analysis with propidium iodide labeling revealed marked decreases in the percentage of KMS-8 cells in S phase and increases in G0-G1 by the addition of myr-PCI(Y). On the other hand, myr-PCI(F), in which two of the tyrosine residues in myr-PCI(Y) are replaced by phenylalanine and which does not inhibit phosphatidylinositol 4,5-bisphosphate-hydrolyzing activity in vitro, did not significantly inhibit either inositol trisphosphate production or cell growth. These results indicate that the activation of PLC is essential for growth and the transformed properties of these colorectal carcinoma cells.
Homma
M K
MK
Department of Hygiene and Oncology, Tokyo Medical and Dental University, Japan.
Homma
Y
Y
Yamasaki
M
M
Ohmi-Imajoh
S
S
Yuasa
Y
Y
D011125:Adenomatous Polyposis Coli; D000595:Amino Acid Sequence; D001769:Blood; D002277:Carcinoma / Q000201:enzymology / Q000378:metabolism* / Q000473:pathology; D002453:Cell Cycle / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D002471:Cell Transformation, Neoplastic / Q000187:drug effects; D015179:Colorectal Neoplasms / Q000201:enzymology / Q000378:metabolism* / Q000473:pathology; D004273:DNA, Neoplasm / Q000096:biosynthesis; D004791:Enzyme Inhibitors / Q000138:chemical synthesis / Q000494:pharmacology*; D006801:Humans; D007295:Inositol Phosphates / Q000096:biosynthesis; D008969:Molecular Sequence Data; D019814:Myristic Acid; D009227:Myristic Acids / Q000737:chemistry; D009842:Oligopeptides / Q000138:chemical synthesis / Q000494:pharmacology*; D015398:Signal Transduction / Q000502:physiology; D014407:Tumor Cells, Cultured; D010738:Type C Phospholipases / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000502:physiology
D004273:DNA, Neoplasm; D004791:Enzyme Inhibitors; D007295:Inositol Phosphates; D009227:Myristic Acids; D009842:Oligopeptides; D019814:Myristic Acid; D010738:Type C Phospholipases